| Next 10 |
Ad
CYTH News and Press Cyclo Therapeutics Inc.
News | Cyclo Therapeutics Inc. (NASDAQ:CYTH)
-
Eyenovia Inc. (EYEN) is expected to report $-8 for Q4 2024 Nemaura Medical Inc. (NMRD) is expected to report for quarter end 2024-12-31 LanzaTech Global Inc. (LNZA) is expected to report $-0.16 for Q4 2024 Investcorp Credit Management BDC Inc. (ICMB) is expected to report for Q2 2025 ...
-
The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol ® Cyclo™ NEWARK, N.J., March 13, 2025 (GLOBE NEWSW...
-
2025-02-07 09:23:14 ET DENVER, Colo., Feb 07, 2025 ( 247marketnews.com )- Cyclo Therapeutics (NASDAQ: CYTH ) reportedly made significant progress in its ongoing Phase 3 TransportNPC study. The study is evaluating Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1 (NPC1...
-
NEWARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the first quarter of fiscal year 2025 ended October 31, 2024. “We anticipate proceeding to a shareholder vote on our pending merger agreement with Cyclo Therapeut...
-
Strategic merger with Rafael Holdings to combine two companies and advance Trappsol ® Cyclo™ for NPC1 patients expected to close Q4 2024 Company on track for topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ in H1 2025 ...
-
NEWARK, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the fourth quarter and the full fiscal year ended July 31, 2024. “During fiscal 2024, we made significant progress on our strategy to advance our existing portfol...
-
TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the appointment of Shawn Cross as Chief Financial Officer. In this role, Mr. Cross will be responsible for overseei...
-
Two posters presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 Pivotal TransportNPC™ study is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for NPC1 ...
-
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.7% to $123.74 on volume of 371,408,669 shares PROSHARES TRUST (SQQQ) rose 4.8% to $8.24 on volume of 193,647,870 shares MicroCloud Hologram Inc. (HOLO) rose 32.2% to $0.6938 on volume of 159,894,543 shar...
-
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 65.1% to $0.1955 on volume of 87,674,058 shares NVIDIA Corporation (NVDA) rose 1.3% to $130.12 on volume of 38,064,116 shares Staffing 360 Solutions Inc. (STAF) rose 240.8% to $4.09 on volume of 32,93...
Stock Information
Get CYTH Alerts
News, Short Squeeze, Breakout and More Instantly...
Cyclo Therapeutics Inc. Company Name:
CYTH Stock Symbol:
NASDAQ Market:
-1.03% G/L:
$0.70 Last:
35,265 Volume:
$0.687 Open:
$0.70 Close:
Cyclo Therapeutics Inc. Website:
Ad
-
Eyenovia Inc. (EYEN) is expected to report $-8 for Q4 2024 Nemaura Medical Inc. (NMRD) is expected to report for quarter end 2024-12-31 LanzaTech Global Inc. (LNZA) is expected to report $-0.16 for Q4 2024 Investcorp Credit Management BDC Inc. (ICMB) is expected to report for Q2 2025 ...
-
The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol ® Cyclo™ NEWARK, N.J., March 13, 2025 (GLOBE NEWSW...
-
2025-02-07 09:23:14 ET DENVER, Colo., Feb 07, 2025 ( 247marketnews.com )- Cyclo Therapeutics (NASDAQ: CYTH ) reportedly made significant progress in its ongoing Phase 3 TransportNPC study. The study is evaluating Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1 (NPC1...